As it became clear that BK was the primary mediator of angioedema symptoms in HAE, and that a dysregulation of BK pathways was responsible for angiodema attack onset, considerable efforts have been devoted to drug development targeted to components of the kallikrein-kinin system. Here, KNG1 is linked to angioedema.